Please select an option below to help us tailor your newsletter to best suit your content interests!
OneR and West Cancer Physicians Give Ten Presentations at SABCS OneOncology, the national network of independent oncology practices, announced today that physicians from OneR, the OneOncology Research Network and West Cancer and Research Institute will share results from ten research studies at the San Antonio Breast Cancer Symposium® (SABCS®), an international gathering of physicians and… Read more »
Axel Grothey, MD The New England Journal of Medicine (NEJM) has recently published an editorial entitled “Pembrolizumab as first-line therapy in mismatch repair-deficient advanced colorectal cancer: A new standard of care” written by West Cancer Center’s GI Medical Oncology Lead and GI Oncology Clinical Research Director, Dr. Axel Grothey. Click the link below… Read more »
Matching patient populations with a targetable genomic alteration to a specific investigational study is the aim of a new clinical trial through OneR and Genentech. This partnership will facilitate collaborations on various clinical trials, scientific research and real-world data studies that will advance personalized cancer care at community oncology centers like West. “With too many… Read more »
West Clinic Offers Patients Even More Oncology Treatment Options West joins launch of new technology platform, OneR, to increase trial therapies for patients As an affiliate of OneOncology, West Clinic now has the ability to further its clinical trial offerings and oncology research knowledge by joining the launch of OneR. OneR is a… Read more »
In an effort to further promote social distancing, patients are now able to schedule certain appointments as televisits to speak with their care team from home. Talk to your care team or contact our scheduling department at 901.683.0055 to see if a televisit is right for you!
Choosing the Right Biosimilar for Cancer Care The introduction of biosimilars as anticancer therapies was preceded by a period of supportive care biosimilars. Lee S. Schwartzberg, MD, FACP, describes how he and other clinicians decide which of these agents to use. Well before biosimilar anticancer agents became available, oncologists gained familiarity using biosimilars… Read more »